UAB coordinates a European project on vaccine research

March 02, 2007

The STREP research project "Assessment of Structural Requirements in Complement-Mediated Bactericidal Events: Towards a Global Approach to the Selection of New Vaccine Candidates1, -BacAbs" has been recently launched by a consortium of nine institutions -academic and industrial- from six European countries, coordinated by Xavier Daura, ICREA Research Professor at the Institute of Biotechnology and Biomedicine of UAB.

The project aims at implementing a novel multidisciplinary approach to investigate the requirements, at the molecular-structure level, for viable (bactericidal) candidates for vaccine assays and developing bioinformatics tools to predict compliance with such requirements, starting from information generated in previous projects by members of the consortium.

High throughput cloning and expression of large sets of genomic ORFs has become a preferred industrial strategy for genome-wide searches of new vaccine candidates. For invasive infections in particular, the aim is to find proteins eliciting antibodies capable of binding to the bacterial cell surface and, through interaction with the complement system, effectively kill the bacteria. However, current data accumulating from reverse vaccinology studies (targeting of possible vaccine candidates starting from genomic information) show that only a small fraction of surface-exposed proteins appears to elicit antibodies with bactericidal activity.

The BacAbs project will undertake a systematic analysis of sequence, structure, dynamics and interactions of selected protein targets using as model system serogroup-B Neisseria meningitidis, a pathogen causing septicemia and meningitis for which no effective vaccine exists.

The Consortium comprises an industrial partner with extensive experience on vaccine development -Novartis Vaccines and Diagnostics, Italy-, three small or medium enterprises with strong expertises on several of the key technological aspects of the project -ASLA Biotech, Latvia; Bio-Xtal, France; INFOCIENCIA, Spain), and five academic partners with groups having internationally recognized tracks on experimental and theoretical studies of protein structure and interactions (Universitat Autònoma de Barcelona, Spain; Consiglio Nazionale delle Ricerche, Italy; International University Bremen, Germany; Università degli Studi di Milano, Italy; Universiteit Utrecht, Netherlands).

With a duration of three years, the project is supported by funding under the Sixth Research Framework Programme of the European Union.
-end-


Universitat Autonoma de Barcelona

Related Vaccine Development Articles from Brightsurf:

New tool outsmarts COVID-19 virus to help vaccine development
Melbourne researchers have developed a tool to monitor mutations that make it difficult to develop coronavirus (COVID-19) vaccines and drugs.

Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Publishing in the journal Nature, researchers from the Univ. of Texas at Austin, Moderna and the NIH explain how they developed the COVID-19 vaccine candidate mRNA-1273 and report strong positive results on its effectiveness in mice.

UCalgary researchers unlock new insights that could help with vaccine development
Researchers at the University of Calgary have unlocked new insights that may help with vaccine development for infectious diseases such as COVID-19, malaria, and tuberculosis.

A nanomaterial path forward for COVID-19 vaccine development
From mRNA vaccines entering clinical trials, to peptide-based vaccines and using molecular farming to scale vaccine production, the COVID-19 pandemic is pushing new and emerging nanotechnologies into the frontlines and the headlines.

Controlled human infection models and SARS-CoV-2 vaccine development
Infecting volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls and is unlikely to advance the current slate of vaccines in advanced development, argues a group of infectious disease experts.

COVID-19 vaccine development: New guidelines for ethical approach to infecting trial volunteers
Allowing consenting volunteers to be deliberately infected with COVID-19 for the purposes of developing a vaccine could be done ethically and potentially speed up its development, a University of Warwick researcher has argued in new research.

New imaging analysis pipeline could aid in drug and vaccine development
A new paper introduces a method to effectively analyze data from lattice light-sheet microscopy, used to closely examine individual cells, such as T-cells, in 4D.

Perspective: Rapid COVID-19 vaccine development
When seeking the fastest pathway to a vaccine to prevent coronavirus disease 19 (COVID-19), defining the stakes and potential hurdles is critical, says Barney Graham in this Perspective.

HKUST scientists shed light on COVID-19 vaccine development
A team HKUST scientists has recently identified a set of potential vaccine targets for SARS-CoV-2 coronavirus, to guide experimental efforts towards vaccine development against novel pneumonia (COVID-19).

Novel model for studying intestinal parasite could advance vaccine development
The intestinal parasite Cryptosporidium causes frequent outbreaks in the US, and has been historically difficult to study.

Read More: Vaccine Development News and Vaccine Development Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.